BTF acquired by bioMerieux

Friday, 14 September, 2007

Australian company BTF Decisive Microbiology has been acquired by bioMerieux. French clinical diagnostics company bioMérieux is present in more than 150 countries through 35 subsidiaries and has a large network of distributors.

The new acquisition will make BTF's products more accessible to a wider distribution network.

Initially, BTF will operate as a standalone subsidiary, so all existing customers will not see any changes in the short term. BTF's contact details remain unchanged.

QIMR Berghofer signs strategic partnership with Nakanoshima Qross

QIMR Berghofer and Japanese biomedical innovation hub Nakanoshima Qross have signed a strategic...

Dr Chris Baldwin is new HaemaLogiX CEO and Managing Director

Having commenced in January, Dr Chris Baldwin is clinical stage Australian biotechnology company...

Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO

To lead the commercialisation of Vaxxas's proprietary high‑density microarray patch (HD‑MAP)...

Content from other channels on our network

Virtual PLCs — a big step forward!

IFR releases position paper on AI in robotics

Australian Vanadium partners with Sumitomo on Kalgoorlie battery bid

Investment in large‍-‍scale renewables surging ahead: report

Open Process Automation: how and where to start

Sexual harassment between doctors — workplace interventions to prevent and minimise harms

Co-editors introduce 'Sexual harassment between doctors' anthology

New Footscray Hospital, Melbourne officially opens to patients

Almost half of Queensland Health doctors meet risk of burnout — survey says

Free live webinar to explain WHS legal obligations in health care

Tip Top Bakeries doubles bread production capacity in WA

Does cultured beef have fewer allergens?

A pinch of saltbush for functional and nutritional benefits

Webinar about PFAS restrictions for food-contact packaging

Unlocking the benefits of avocados across the value chain